Author

Michael Chiorean 1

1 Virginia Mason Medical Center,Seattle,United States

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF A SELECTIVE, ORAL SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATOR, ETRASIMOD (APD334), IN MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS FROM THE OASIS STUDY

William Sandborn, Laurent Peyrin-Biroulet, Luba Trokan, Jinkun Zhang, Tanja Kühbacher, Michael Chiorean, Scott D. Lee, Severine Vermeire, Bruce Yacyshyn, Snehal U. Naik, Preston Klassen, Julian Panés

ANALYSIS OF INFECTIONS OF INTEREST IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME

Alessandro Armuzzi, Christina Ha, Michael Chiorean, Nervin Lawendy, Rajiv Mundayat, Leonardo Salese, John C. Woolcott, Chinyu Su, Iris Dotan

ASSOCIATION BETWEEN DURATION OF LATEST FLARE BEFORE INDUCTION TREATMENT WITH TOFACITINIB AND EFFICACY OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS

Geert D’Haens, Alessandro Armuzzi, Chinyu Su, Xiang Guo, Irene Modesto, Rajiv Mundayat, David P. Hudesman, Michael Chiorean

CHROMOENDOSCOPY IS SUPERIOR TO WHITE LIGHT ENDOSCOPY FOR THE DETECTION OF ADVANCED COLONIC NEOPLASIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Michael Chiorean, Kyeong Ok Kim

CHROMOENDOSCOPY IS SUPERIOR TO WHITE LIGHT ENDOSCOPY FOR THE DETECTION OF ADVANCED COLONIC NEOPLASIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Michael Chiorean

COMPARATIVE EVALUATION OF TREATMENT PERSISTENCE AND DOSE INTENSIFICATION IN PATIENTS WITH CROHN'S DISEASE TREATED WITH USTEKINUMAB VERSUS VEDOLIZUMAB

Michael Chiorean, Jeanne Jiang, Ninfa Candela, Grace Chen, Hela Romdhani, Dominick Latremouille-Viau, Sherry Shi, Rebecca Bungay, Tao Fan

COMPARATIVE EVALUATION OF TREATMENT PERSISTENCE AND DOSE INTENSIFICATION IN PATIENTS WITH CROHN'S DISEASE TREATED WITH USTEKINUMAB VERSUS VEDOLIZUMAB

Michael Chiorean

EARLY AND DURABLE SYMPTOM CONTROL IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH ETRASIMOD (APD334) IN THE RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 OASIS TRIAL AND OPEN LABEL EXTENSION

Michael Chiorean

EARLY AND DURABLE SYMPTOM CONTROL IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH ETRASIMOD (APD334) IN THE RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 OASIS TRIAL AND OPEN LABEL EXTENSION

Michael Chiorean, Severine Vermeire, Julian Panés, Laurent Peyrin-Biroulet, Jinkun Zhang, Bruce E. Sands, Chris Cabell, Snehal U. Naik, William Sandborn

EARLY AND DURABLE SYMPTOM CONTROL IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH ETRASIMOD (APD334) IN THE RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 OASIS TRIAL AND OPEN LABEL EXTENSION

Michael Chiorean

Item 1 - 10 / 19
1
2